Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Pharma & Biotech

CSL shares surge 15% as investors look past loss to stronger FY27 outlook

CSL Limited (ASX:CSL) investors shrugged off the company’s hefty loss, instead focusing on stronger-than-expected FY27 earnings guidance, while Brookfield’s improved bid has put Reliance back in the spotlight.

CSL shares jumped 15% to $154.43 in the opening minutes of trade. By midday, shares were 16.71% higher.

Ahead of the market open, RBC Capital Markets analyst Craig Wong-Pan said CSL had “delivered a good FY26 result with beats across revenue, EBITDA and NPATA”.

“Compositionally, all segments exceeded revenue and gross profit expectations,” Wong-Pan said.

He calculated CSL’s guidance as implying FY27 constant-currency profit of about US$2.98 billion and underlying NPAT of around US$2.93 billion.

“The stock has had a strong run into this result, however we expect the FY27 guidance beat to consensus and strong Ig performance in 2H26 to drive outperformance in the stock today,” Wong-Pan said.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK